Correlated Drug Terms (4)

---

	Name (Synonyms)	Correlation
drug2289	Spironolactone 100mg Wiki	0.50
drug142	Alirocumab Wiki	0.25
drug1853	Placebo oral tablet Wiki	0.09
drug1822	Placebo Wiki	0.03

Correlated MeSH Terms (3)

---

	Name (Synonyms)	Correlation
D055371	Acute Lung Injury NIH	0.05
D012127	Respiratory Distress Syndrome, Newborn NIH	0.05
D012128	Respiratory Distress Syndrome, Adult NIH	0.04

Correlated HPO Terms (0)

---

	Name (Synonyms)	Correlation

Primary Outcomes

Description: The values and variability of AUEC for LDL-C at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab

Measure: Area under effect curve (AUEC) for LDL-C for evolocumab and alirocumab

Time: 42, 56, or 84 days, depending on treatment arm

---

Description: The values and variability of maximum change from baseline for LDL-C at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab

Measure: Maximum change from baseline for LDL-C for evolocumab and alirocumab

Time: 42, 56, or 84 days, depending on treatment arm

---

Secondary Outcomes

Description: The values and variability of AUEC for ApoB at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab

Measure: AUEC for Apolipoprotein B (ApoB) for evolocumab and alirocumab

Time: 42, 56, or 84 days, depending on treatment arm

---

Description: The values and variability of maximal difference at a single time-point for ApoB at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab

Measure: Maximum change from baseline for apoB for evolocumab and alirocumab

Time: 42, 56, or 84 days, depending on treatment arm

---

Description: The values and variability of Cmax at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab

Measure: Maximum concentration (Cmax) for evolocumab and alirocumab

Time: 42, 56, or 84 days, depending on treatment arm

---

Description: The values and variability of AUC at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab

Measure: Area under the curve (AUC) for evolocumab and alirocumab

Time: 42, 56, or 84 days, depending on treatment arm

---

Description: Model parameters (Emax) calculated after combining data from low, intermediate low, intermediate high, and high doses of evolocumab or alirocumab with placebo data.

Measure: Pharmacodynamic model parameters (maximum effect [Emax]) for evolocumab and alirocumab

Time: 42, 56, or 84 days, depending on treatment arm

---

Description: Model parameters (EC50) calculated after combining data from low, intermediate low, intermediate high, and high doses of evolocumab or alirocumab with placebo data.

Measure: Pharmacodynamic model parameters (half maximum effect concentration [EC50]) for evolocumab and alirocumab

Time: 42, 56, or 84 days, depending on treatment arm

---

Primary Outcomes

Description: The values and variability of AUEC for LDL-C at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab

Measure: Area under effect curve (AUEC) for LDL-C for evolocumab and alirocumab

Time: 42, 56, or 84 days, depending on treatment arm

---

Description: The values and variability of maximum change from baseline for LDL-C at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab

Measure: Maximum change from baseline for LDL-C for evolocumab and alirocumab

Time: 42, 56, or 84 days, depending on treatment arm

---

Secondary Outcomes

Description: The values and variability of AUEC for ApoB at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab

Measure: AUEC for Apolipoprotein B (ApoB) for evolocumab and alirocumab

Time: 42, 56, or 84 days, depending on treatment arm

---

Description: The values and variability of maximal difference at a single time-point for ApoB at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab

Measure: Maximum change from baseline for apoB for evolocumab and alirocumab

Time: 42, 56, or 84 days, depending on treatment arm

---

Description: The values and variability of Cmax at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab

Measure: Maximum concentration (Cmax) for evolocumab and alirocumab

Time: 42, 56, or 84 days, depending on treatment arm

---

Description: The values and variability of AUC at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab

Measure: Area under the curve (AUC) for evolocumab and alirocumab

Time: 42, 56, or 84 days, depending on treatment arm

---

Description: Model parameters (Emax) calculated after combining data from low, intermediate low, intermediate high, and high doses of evolocumab or alirocumab with placebo data.

Measure: Pharmacodynamic model parameters (maximum effect [Emax]) for evolocumab and alirocumab

Time: 42, 56, or 84 days, depending on treatment arm

---

Description: Model parameters (EC50) calculated after combining data from low, intermediate low, intermediate high, and high doses of evolocumab or alirocumab with placebo data.

Measure: Pharmacodynamic model parameters (half maximum effect concentration [EC50]) for evolocumab and alirocumab

Time: 42, 56, or 84 days, depending on treatment arm

---

Primary Outcomes

Description: The values and variability of AUEC for LDL-C at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab

Measure: Area under effect curve (AUEC) for LDL-C for evolocumab and alirocumab

Time: 42, 56, or 84 days, depending on treatment arm

---

Description: The values and variability of maximum change from baseline for LDL-C at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab

Measure: Maximum change from baseline for LDL-C for evolocumab and alirocumab

Time: 42, 56, or 84 days, depending on treatment arm

---

Secondary Outcomes

Description: The values and variability of AUEC for ApoB at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab

Measure: AUEC for Apolipoprotein B (ApoB) for evolocumab and alirocumab

Time: 42, 56, or 84 days, depending on treatment arm

---

Description: The values and variability of maximal difference at a single time-point for ApoB at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab

Measure: Maximum change from baseline for apoB for evolocumab and alirocumab

Time: 42, 56, or 84 days, depending on treatment arm

---

Description: The values and variability of Cmax at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab

Measure: Maximum concentration (Cmax) for evolocumab and alirocumab

Time: 42, 56, or 84 days, depending on treatment arm

---

Description: The values and variability of AUC at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab

Measure: Area under the curve (AUC) for evolocumab and alirocumab

Time: 42, 56, or 84 days, depending on treatment arm

---

Description: Model parameters (Emax) calculated after combining data from low, intermediate low, intermediate high, and high doses of evolocumab or alirocumab with placebo data.

Measure: Pharmacodynamic model parameters (maximum effect [Emax]) for evolocumab and alirocumab

Time: 42, 56, or 84 days, depending on treatment arm

---

Description: Model parameters (EC50) calculated after combining data from low, intermediate low, intermediate high, and high doses of evolocumab or alirocumab with placebo data.

Measure: Pharmacodynamic model parameters (half maximum effect concentration [EC50]) for evolocumab and alirocumab

Time: 42, 56, or 84 days, depending on treatment arm

---

Primary Outcomes

Description: The values and variability of AUEC for LDL-C at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab

Measure: Area under effect curve (AUEC) for LDL-C for evolocumab and alirocumab

Time: 42, 56, or 84 days, depending on treatment arm

---

Description: The values and variability of maximum change from baseline for LDL-C at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab

Measure: Maximum change from baseline for LDL-C for evolocumab and alirocumab

Time: 42, 56, or 84 days, depending on treatment arm

---

Secondary Outcomes

Description: The values and variability of AUEC for ApoB at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab

Measure: AUEC for Apolipoprotein B (ApoB) for evolocumab and alirocumab

Time: 42, 56, or 84 days, depending on treatment arm

---

Description: The values and variability of maximal difference at a single time-point for ApoB at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab

Measure: Maximum change from baseline for apoB for evolocumab and alirocumab

Time: 42, 56, or 84 days, depending on treatment arm

---

Description: The values and variability of Cmax at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab

Measure: Maximum concentration (Cmax) for evolocumab and alirocumab

Time: 42, 56, or 84 days, depending on treatment arm

---

Description: The values and variability of AUC at low, intermediate low, intermediate high, and high doses of evolocumab and alirocumab

Measure: Area under the curve (AUC) for evolocumab and alirocumab

Time: 42, 56, or 84 days, depending on treatment arm

---

Description: Model parameters (Emax) calculated after combining data from low, intermediate low, intermediate high, and high doses of evolocumab or alirocumab with placebo data.

Measure: Pharmacodynamic model parameters (maximum effect [Emax]) for evolocumab and alirocumab

Time: 42, 56, or 84 days, depending on treatment arm

---

Description: Model parameters (EC50) calculated after combining data from low, intermediate low, intermediate high, and high doses of evolocumab or alirocumab with placebo data.

Measure: Pharmacodynamic model parameters (half maximum effect concentration [EC50]) for evolocumab and alirocumab

Time: 42, 56, or 84 days, depending on treatment arm

---